IP Library Granted Patent US 12662685
Granted Patent B2
US 12662685 · App. 17/271,814 · Granted Jun 23, 2026

Self-inactivating transposase plasmids and uses thereof

Inventors: Michael C. Jensen (Seattle, WA); Joshua Gustafson (Seattle, WA); Joseph Cheng (Seattle, WA); Rachel Wilson (Seattle, WA); Kamila Sabina Gwiazda (Seattle, WA); Jeremy Bjelajac (Seattle, WA)
Assignee: Seattle Children's Hospital
C12N15/85C12N2800/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662685
App. No.
17/271,814
Granted
Jun 23, 2026
Kind
B2
Abstract

Some embodiments provided herein relate to gene delivery systems and methods using a single plasmid that carries a self-inactivating transposase gene and a corresponding transposon. Some embodiments include nucleic acids having certain sequences, vector including such nucleic acids, and compositions including the vectors.

Claims (18)

1 . A vector for delivery of a payload into a cell genome, the vector comprising (a), (b), and (c) in a 5′ to 3′ order:

(a) a first nucleic acid comprising (i) a nucleotide sequence encoding a transposase, and (ii) an intron comprising a first transposase recognition site (TRS), wherein the intron is inserted into the nucleotide sequence encoding the transposase;

(b) a second nucleic acid encoding the payload; and

(c) a second TRS.

2 . The vector of claim 1 , wherein the vector is a circular vector.

3 . The vector of claim 1 , wherein the transposase is a Tn5 transposase, a MuA transposase, a Tn552 transposase, or a mariner transposase.

4 . The vector of claim 1 , wherein the transposase is encoded by a sequence having at least 90% sequence identity to the nucleotide sequence of SEQ ID NO:01 or SEQ ID NO:03.

5 . The vector of claim 1 , wherein the intron is derived from a nucleic acid lacking the first TRS and, wherein the nucleic acid lacking the first TRS comprises a sequence having at least 90% sequence identity to the nucleotide sequence of SEQ ID NO:02.

6 . The vector of claim 1 , wherein the first TRS and the second TRS are both derived from a transposon selected from a Tn5 transposon, a MuA transposon, a Tn552 transposon, or a mariner transposon.

7 . The vector of claim 1 , wherein the first TRS and the second TRS comprise a sequence having at least 90% sequence identity to the nucleotide sequence of SEQ ID NO:05 or SEQ ID NO:13.

8 . The vector of claim 1 , wherein the payload encodes a therapeutic protein.

9 . The vector of claim 1 , further comprising a first promoter operably linked to the first nucleic acid.

10 . The vector of claim 1 , further comprising a selectable marker.

11 . The vector of claim 10 , wherein the selectable marker encodes a dihydrofolate reductase (DHFR).

12 . The vector of claim 1 , further comprising a nucleic acid encoding a first polyA signal operably linked to the second nucleic acid, or a second polyA signal operably linked to the third nucleic acid.

13 . A cell comprising the vector of claim 1 .

14 . The cell of claim 13 , wherein the cell is a mammalian cell.

15 . The cell of claim 14 , wherein the cell is a human cell.